A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Documenti analoghi

• Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
  di: Carbone, Alessia, et al.
  Pubblicazione: (2014)
• Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
  di: Spagnuolo, Vincenzo, et al.
  Pubblicazione: (2014)
• Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
  di: Gianotti, Nicola, et al.
  Pubblicazione: (2016)
• Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
  di: Ferretti, Francesca, et al.
  Pubblicazione: (2016)
• Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
  di: Gianotti, Nicola, et al.
  Pubblicazione: (2017)